ArticleACS pharmacology & translational science2020
Auranofin-Based Analogues Are Effective Against Clear Cell Renal Carcinoma
Article in ACS pharmacology & translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Multifunctional auranofin analogues: dual-targeting TSPO/TrxR gold(I) complexes with activity in resistant ovarian cancer.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Article
- Tuning Au Reactivity Beyond Canonical Targets: Ligand-Driven Au(I) Metalation of Lysine Residues in Hen Egg White Lysozyme.Inorganic chemistry · 2026Article
- Biomaterial-Driven Integrated Therapy for Renal Cell Carcinoma: Renal Cancer Control and Kidney Injury Repair.Research (Washington, D.C.) · 2026Review
- Welcoming Neighbour or Inhospitable Host? Selective Second Metal Binding in 5- and 6-Phospha-Substituted Bpy Ligands.Molecules (Basel, Switzerland) · 2024Article
- Development of immunoliposomes containing cytotoxic gold payloads against HER2-positive breast cancers.RSC medicinal chemistry · 2024Article
- Shifting the Antibody-Drug Conjugate Paradigm: A Trastuzumab-Gold-Based Conjugate Demonstrates High Efficacy against Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Mouse Model.ACS pharmacology & translational science · 2023Article
- Platinum(IV)-Gold(I) Agents with Promising Anticancer Activity: Selected Studies in 2D and 3D Triple-Negative Breast Cancer Models.Chemistry (Weinheim an der Bergstrasse, Germany) · 2023Article
- A complex bearing TSPO PIGA ligand coordinated to the [Au(PEtBiometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023Article
- Promising heterometallic compounds as anticancer agents: Recent studies in vivo.Current opinion in chemical biology · 2023Review
- Article
- Current Progress and Perspectives on Using Gold Compounds for the Modulation of Tumor Cell Metabolism.Frontiers in chemistry · 2021Review
- An Organometallic Gold(I) Bis-N-Heterocyclic Carbene Complex with Multimodal Activity in Ovarian Cancer Cells.Chemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
- SEC hyphenated to a multielement-specific detector unravels the degradation pathway of a bimetallic anticancer complex in human plasma.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Effective pharmacological treatments for patients with advanced clear cell renal carcinoma (ccRCC) are limited. Bimetallic titanium-gold containing compounds exhibit significant cytotoxicity against ccRCC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.